Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Isis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01234025
First received: November 2, 2010
Last updated: November 1, 2012
Last verified: November 2012

November 2, 2010
November 1, 2012
November 2010
September 2013   (final data collection date for primary outcome measure)
Progression free survival [ Time Frame: At the end of each 21 day cycle ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01234025 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer

The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Castrate-Resistant Prostate Cancer
  • Drug: ISIS EIF4E Rx
    800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
  • Drug: ISIS EIF4E Rx
    1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
  • Drug: ISIS EIF4E Rx
    (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
  • Drug: Prednisone
    5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
  • Drug: Docetaxel
    75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
  • Experimental: Part 1 Cohort 1
    Interventions:
    • Drug: ISIS EIF4E Rx
    • Drug: Prednisone
    • Drug: Docetaxel
  • Experimental: Part 1 Cohort 2
    Interventions:
    • Drug: ISIS EIF4E Rx
    • Drug: Prednisone
    • Drug: Docetaxel
  • Experimental: Part 2 Arm A
    Interventions:
    • Drug: Prednisone
    • Drug: Docetaxel
  • Experimental: Part 2 Arm B
    Interventions:
    • Drug: ISIS EIF4E Rx
    • Drug: Prednisone
    • Drug: Docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
112
March 2015
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provide written informed consent prior to Screening.
  • Age ≥ 18 years.
  • Histological or cytological diagnosis of adenocarcinoma of the prostate.
  • Metastatic disease for which no curative therapy exists and for which systemic chemotherapy is indicated.
  • Progression of disease despite either medical or surgical castration. If the patient received medical androgen ablation, a castrate level of testosterone (> or = 50 ng/dL) must have been present concurrent with disease progression. Progressive disease is defined as any one of the following:

    • Rising serum PSA levels: two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart with the value of the third point being ≥ 2 ng/mL. If the third PSA level is less than the second, an additional fourth test to confirm a rising PSA (i.e., the fourth value is ≥ the second value and is ≥ 2 ng/mL) is acceptable.
    • Progressive measurable disease defined as an increase in the sum of the diameters of measurable lesions over the smallest sum observed or the appearance of one or more new lesions as assessed by CT scan.
    • Bone progressions: appearance of 2 or more new lesions on bone scan or other imaging.
  • If patient did not have a surgical orchiectomy:

    • The patient must be on androgen suppression treatment (e.g. LHRH agonist), have a castrate level of testosterone (< or = 50 ng/dL), and must be willing to continue the treatment throughout the study.
    • The patient must have discontinued treatment with anti-androgens (discontinued ≥ 4 weeks for flutamide and ≥ 6 weeks for nilutamide or bicalutamide prior to Screening) and have documented disease progression following discontinuation.
  • PSA > or = 2 ng/mL during the Screening period.
  • Performance status of 0 or 1 on the ECOG Performance Status Scale.
  • Have an estimated life expectancy of at least 12 weeks.
  • Adequate organ function within 14 days prior to first study dose (ISIS EIF4E Rx or docetaxel, whichever occurs first) including the following:

    • Absolute neutrophil count (ANC) > or = 1.5 x 109/L.
    • Platelet count > or = 100 x 109/L.
    • Total bilirubin < or = 1.0 x upper limit of normal (ULN).
    • Aspartate aminotransferase (AST) < or = 1.5 x ULN.
    • Alanine aminotransferase (ALT) < or = 1.5 x ULN.
    • Serum creatinine < or = 1.5 x ULN.
    • Prothrombin time (PT) and international normalized ratio (INR) within normal limits.
    • Activated partial thromboplastin time (aPTT) within normal limits.
  • Part 1: Have had no more than 1 prior chemotherapy or biological therapy regimen (approved or experimental; all previous hormonal therapies are allowed and not counted as biological therapy for this inclusion criterion) for prostate cancer. This does not include treatments that may have been received in the adjuvant or neoadjuvant setting. A regimen is defined as two or more consecutive cycles of treatment. Part 2: Have had no prior chemotherapy or biological therapy (approved or experimental; all previous hormonal therapies are allowed and not counted as biological therapy for this inclusion criterion) in any setting for prostate cancer.
  • Have discontinued all previous therapies for cancer (except treatment with LHRH analogues) as follows:

    • Part 1: cytotoxic chemotherapy must be discontinued at least 4 weeks prior to screening; Part 2: see Inclusion Criteria 11.
    • Part 1: biological treatment (other than hormonal treatments) must be discontinued for at least 6 weeks prior to screening; Part 2: see Inclusion Criteria 11.
    • Hormone therapies (e.g., abiraterone, MDV3100) must have been discontinued 4 weeks prior to screening.
    • Radiotherapy must be discontinued at least 4 weeks prior to screening, and the patient must have recovered from the acute effects of therapy.
  • Recovery from all toxicities of prior therapy to ≤ Grade 2 by NCI CTCAE, version 4.0 (Exception: any toxicity that in the view of the Investigator is not a clinically significant safety risk for further therapy administration, including, but not limited to: anemia, fatigue, erectile dysfunction, hot flashes, lymphedema of an extremity, dizziness, cough, and urinary incontinence).
  • Men of reproductive potential must agree to use an effective form of contraception, as determined by the Investigator, during the treatment period of the study and for 10 weeks following the last dose of study drug.
  • The patient is willing and able to comply with the study visit schedule and procedures, and geographic proximity (Investigator's discretion) that allows adequate follow-up.

Exclusion Criteria:

  • Treatment with another investigational drug or device within 4 weeks or biological agent within 6 weeks before Screening or 5 half-lives of study agent, whichever is longer.
  • Pre-existing peripheral neuropathy > or = Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE) Grade 2.
  • Patients with treated or untreated parenchymal brain metastases or leptomeningeal disease. Currently active malignant epidural disease is also excluded. Previously treated epidural disease does not exclude the patient from the study. (Note: CT or MRI of brain is not needed to rule these out unless the patient has clinical symptoms suggestive of CNS metastases).
  • Have active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator).
  • Presence or history of other malignancies except non-melanoma skin cancer or solid tumors curatively treated at least 5 years previously with no subsequent evidence of recurrence.
  • Presence of an underlying disease state associated with active bleeding.
  • Ongoing therapy with oral or parenteral anticoagulants (e.g., heparin, warfarin/coumadin). Low-dose anticoagulants for maintenance of catheter patency and low dose aspirin (≤ 325 mg/day) and nonsteroidal antiinflammatory agents are not exclusionary.
  • Concurrent treatment with other anticancer drugs.
  • Inability to comply with protocol or study procedures.
  • Previous therapy with strontium or samarium.
  • Patients who have had irradiation of ≥ 25% of the bone marrow (e.g. pelvic irradiation).
  • Use of any herbal products, including saw palmetto within 1 week of screening and throughout the study.
  • Initiation of treatment with bisphosphonates, or change in dose, within 4 weeks of assignment to dosing in this study. Patients taking bisphosphonates should not have their dosing regimen altered during the study unless medically warranted.
  • Known history of HIV, HCV, or chronic HBV infection.
  • Previous treatment with a therapeutic antisense oligonucleotide or siRNA.
  • Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device.
  • Have any other medical conditions that, in the opinion of the Investigator, would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Romania,   Poland,   Russian Federation,   United States,   Hungary,   Puerto Rico
 
NCT01234025
ISIS 183750-CS3
No
Isis Pharmaceuticals
Isis Pharmaceuticals
Not Provided
Not Provided
Isis Pharmaceuticals
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP